RT Journal Article
SR Electronic
T1 Searching for prognostic biomarkers of Parkinson’s Disease development in the Spanish EPIC cohort through a multiplatform metabolomics approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.02.21252744
DO 10.1101/2021.03.02.21252744
A1 Carolina Gonzalez-Riano
A1 Jorge Saiz
A1 Coral Barbas
A1 Alberto Bergareche
A1 José Ma Huerta
A1 Eva Ardanaz
A1 Marcela Konjevod
A1 Elisabet Mondragon
A1 ME Erro
A1 M. Dolores Chirlaque
A1 Eunate Abilleira
A1 Fernando Goñi-Irigoyen
A1 Pilar Amiano
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.03.02.21252744.abstract
AB Objective The lack of knowledge about the onset and progression of Parkinson’s disease (PD) hampers its early diagnosis and treatment. Our aim was to determine the biochemical remodeling induced by PD in a really early and pre-symptomatic stage and unveiling early potential diagnostic biomarkers adopting a multiplatform (LC-MS, GC-MS, CE-MS) untargeted metabolomics approach.Methods 41,437 healthy volunteers from the European Prospective Study on Nutrition and Cancer (EPIC)-Spain cohort were followed for around 15 years to ascertain incident PD. For this study, baseline pre-clinical plasma samples of 39 randomly selected individuals (46% females, 41– 69 years old) that developed PD (Pre-PD group) and the corresponding control group (n=39, 46% females, 41–69 years old) were analyzed. The metabolic differences were investigated by univariate and multivariate data analyses, followed by pathway-based metabolite analyses to obtain possible clues on biological functions.Results Our results exposed significantly lower levels of seven free fatty acids in the pre-PD subjects, together with alterations in other metabolite classes. Our finding revealed alterations in fatty acids metabolism, mitochondrial dysfunction, oxidative stress, and gut-brain axis dysregulation.Conclusions Although the biological purpose of these events is still unknown, the mechanisms involved in the remodelling of the suggested metabolic pathways seem to appear long before the development of PD hallmarks. These findings might be considered as worthy potential markers whose alteration might lead to the development of PD hallmarks in the future. Consequently, this study is of inestimable value since this is the first study conducted with samples collected many years before the disease development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the following entities: Basque Government, Spain (GV2016111098), the Spanish Ministry of Science, Innovation and Universities (grant RTI2018-095166-B-I00 to C.B.), and FEDER Program 2014-2020 of the Community of Madrid (S2017/BMD3684).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval and consent to participate: This study was approved by the Ethics Committee for clinical research of the Basque Country PI2017031. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.BAbile acidsCMPF3-carboxy-4-methyl-5-propyl-2-furanpropionic acidDPAdocosapentaenoic acidEPICEuropean Prospective Study on Nutrition and CancerFFAsfree fatty acidsLPClysoglycerophosphocholinesMFAmonounsaturated fatty acidMPP+1-Methyl-4-phenylpyridiniumMPTP1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinePCglycerophosphocholinespre-PDpre-Parkinson’s Disease development groupPUFApolyunsaturated fatty acidQC-SVRCquality control samples and support vector regressionRMTrelative migration timeSFAsaturated fatty acidSVMSupport Vector Machine.